Co-Authors
This is a "connection" page, showing publications co-authored by Ruiwen Zhang and Wei Wang.
Connection Strength
9.658
-
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways. Front Pharmacol. 2025; 16:1531667.
Score: 0.992
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
Score: 0.939
-
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable? Genes Dis. 2025 Mar; 12(2):101156.
Score: 0.906
-
Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel). 2020 Dec 05; 12(12).
Score: 0.741
-
Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells. 2020 05 09; 9(5).
Score: 0.712
-
Corrigendum to "A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance" [Genes Dis 694 (2019) 419-430]. Genes Dis. 2020 03; 7(1):160-161.
Score: 0.695
-
Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880.
Score: 0.684
-
A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019 Dec; 6(4):419-430.
Score: 0.670
-
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167.
Score: 0.668
-
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667.
Score: 0.635
-
Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 07 30; 39(8):1026-1036.
Score: 0.630
-
Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021 03; 41(2):961-1021.
Score: 0.184
-
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
Score: 0.183
-
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7).
Score: 0.180
-
Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018 Sep; 5(3):204-219.
Score: 0.157
-
Inhibiting ?-Catenin by ?-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018; 9:5.
Score: 0.152
-
Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017; 8:917.
Score: 0.151
-
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Prog Mol Biol Transl Sci. 2017; 151:195-216.
Score: 0.148
-
Structural studies of antitumor compounds that target the RING domain of MDM2. Protein Sci. 2022 Aug; 31(8):e4367.
Score: 0.052
-
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. Oncogene. 2021 Aug; 40(33):5182-5191.
Score: 0.048
-
Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression. Int J Mol Sci. 2021 Mar 02; 22(5).
Score: 0.047
-
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866.
Score: 0.046
-
QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Med Chem Res. 2018 Dec; 27(11-12):2466-2481.
Score: 0.040